The FDA has approved AstraZeneca’s IMFINZI combined with standard FLOT chemotherapy for adults with resectable, early-stage ...
Xmoor Pharma and Royal Free London NHS Foundation Trust have patrnered to build a seamless, scalable pathway for CGT ...
The European Commission has approved Sanofi and Regeneron’s Dupixent for the treatment of moderate-to-severe chronic spontaneous urticaria.
Marks Breyanzi’s fourth indication in Europe, adding to existing approvals for several aggressive B-cell lymphomas.
BioMed X has launched a new collaborative research project with AbbVie, hosted at the BioMed X Institute in New Haven, ...
The Future of Oral Solids explores how innovation, advanced manufacturing, and integrated CDMO partnerships are reshaping the ...
AstraZeneca is investing $2 billion to expand its long-standing manufacturing footprint in Maryland. This includes an ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback